当前位置:
X-MOL 学术
›
Blood Cancer J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2017-07-29 , DOI: 10.1038/bcj.2017.69 L Besse 1 , M Kraus 1 , A Besse 1 , J Bader 1 , T Silzle 1 , T Mehrling 2 , C Driessen 1
中文翻译:
一流的烷基化HDAC抑制剂EDO-S101与蛋白酶体通过多种途径激活对多发性骨髓瘤的抑制作用高度协同。
更新日期:2019-11-01
Blood Cancer Journal ( IF 12.9 ) Pub Date : 2017-07-29 , DOI: 10.1038/bcj.2017.69 L Besse 1 , M Kraus 1 , A Besse 1 , J Bader 1 , T Silzle 1 , T Mehrling 2 , C Driessen 1
Affiliation
中文翻译:
一流的烷基化HDAC抑制剂EDO-S101与蛋白酶体通过多种途径激活对多发性骨髓瘤的抑制作用高度协同。